Description of Session
The Enhanced Visual Assessment (EVA) System is a mobile and affordable colposcope that will dramatically transform cervical cancer screening in two critical ways. As a mobile and affordable colposcope, the EVA System drastically improves accessibility to expert care by enabling portability, remote collaboration, and online medical documentation. The Augmented Intelligence (AI) breakthrough of the Automated Visual Evaluation (AVE) algorithm announced by the US National Cancer Institute in January 2019, will enable healthcare providers to detect cervical cancer at the point-of-care in less than one second, with a single cervical image taken on the EVA device, enabling a ‘screen and treat’ offering to be available worldwide. AVE has been validated by the NCI to be significantly more accurate than even the most advanced Pap liquid based cytology. The smartphone based EVA System platform will make AVE globally available to healthcare workers and ensure that every woman screened is directed to appropriate treatment and monitored to ensure her health. AI can eliminate cervical cancer, if given the chance. The AI-enabled EVA System enables healthcare providers to leapfrog restrictions due to lack of laboratory infrastructure, sample collection, and processing time of days or weeks (which leads to massive loss-to-follow-up). By making the EVA System available on a per-use basis, charging for each AI-enabled test individually, MobileODT is able to make screening technology available to healthcare providers at a fraction of the price of existing tests, so that lack of money will not be a reason for lack of care for women, and geography will not determine the dreadful destiny of death by cervical cancer. MobileODT has will discuss how we are working with global partners to further validate and popularize AI on the EVA System, ensuring all women have access to cervical cancer screening.
